San Francisco, United States
Aiolos Bio, founded in 2023, is a promising biopharmaceutical startup revolutionizing treatment approaches for respiratory diseases and immunological disorders. Based in the San Francisco Bay Area with additional operations in London, UK, the company is focused on developing an innovative anti-TSLP therapy that holds best-in-class potential.
Operating within the Biopharma, Biotechnology, and Health Care industries, Aiolos Bio benefits from a team of experienced drug developers. These professionals have a track record of successful therapeutics in immune-related conditions such as asthma and rheumatoid arthritis. Their expertise positions the company to make a significant impact on patient care by reducing treatment burdens.
The company recently secured a substantial $245M Series A investment on 24 October 2023, backed by key players like Atlas Venture, RA Capital Management, Forbion, Sofinnova Investments, and Bain Capital Life Sciences. This strategic funding reinforces its journey towards transformative therapeutic solutions.
